PortfoliosLab logoPortfoliosLab logo
ANIP vs. TARS
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ANIP vs. TARS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ANI Pharmaceuticals, Inc. (ANIP) and Tarsus Pharmaceuticals, Inc. (TARS). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ANIP vs. TARS - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
ANIP
ANI Pharmaceuticals, Inc.
-2.58%42.80%0.25%37.06%-12.70%58.68%-2.52%
TARS
Tarsus Pharmaceuticals, Inc.
-14.33%47.88%173.43%38.13%-34.84%-45.56%100.83%

Fundamentals

Market Cap

ANIP:

$1.63B

TARS:

$3.00B

EPS

ANIP:

$3.75

TARS:

-$1.56

PS Ratio

ANIP:

1.82

TARS:

6.62

PB Ratio

ANIP:

3.02

TARS:

8.74

Total Revenue (TTM)

ANIP:

$883.37M

TARS:

$451.36M

Gross Profit (TTM)

ANIP:

$610.19M

TARS:

$420.68M

EBITDA (TTM)

ANIP:

$225.70M

TARS:

-$60.20M

Returns By Period

In the year-to-date period, ANIP achieves a -2.58% return, which is significantly higher than TARS's -14.33% return.


ANIP

1D
4.33%
1M
4.06%
YTD
-2.58%
6M
-16.05%
1Y
14.86%
3Y*
24.63%
5Y*
17.71%
10Y*
8.52%

TARS

1D
4.83%
1M
-7.11%
YTD
-14.33%
6M
18.04%
1Y
36.56%
3Y*
77.38%
5Y*
16.33%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ANIP vs. TARS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ANIP
ANIP Risk / Return Rank: 5454
Overall Rank
ANIP Sharpe Ratio Rank: 5757
Sharpe Ratio Rank
ANIP Sortino Ratio Rank: 5454
Sortino Ratio Rank
ANIP Omega Ratio Rank: 5252
Omega Ratio Rank
ANIP Calmar Ratio Rank: 5353
Calmar Ratio Rank
ANIP Martin Ratio Rank: 5252
Martin Ratio Rank

TARS
TARS Risk / Return Rank: 6767
Overall Rank
TARS Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
TARS Sortino Ratio Rank: 6767
Sortino Ratio Rank
TARS Omega Ratio Rank: 6262
Omega Ratio Rank
TARS Calmar Ratio Rank: 6969
Calmar Ratio Rank
TARS Martin Ratio Rank: 6565
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ANIP vs. TARS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ANI Pharmaceuticals, Inc. (ANIP) and Tarsus Pharmaceuticals, Inc. (TARS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ANIPTARSDifference

Sharpe ratio

Return per unit of total volatility

0.40

0.81

-0.40

Sortino ratio

Return per unit of downside risk

0.93

1.46

-0.54

Omega ratio

Gain probability vs. loss probability

1.11

1.17

-0.06

Calmar ratio

Return relative to maximum drawdown

0.48

1.35

-0.87

Martin ratio

Return relative to average drawdown

0.97

2.68

-1.71

ANIP vs. TARS - Sharpe Ratio Comparison

The current ANIP Sharpe Ratio is 0.40, which is lower than the TARS Sharpe Ratio of 0.81. The chart below compares the historical Sharpe Ratios of ANIP and TARS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ANIPTARSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.40

0.81

-0.40

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.38

0.27

+0.10

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.18

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.05

0.39

-0.44

Correlation

The correlation between ANIP and TARS is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

ANIP vs. TARS - Dividend Comparison

Neither ANIP nor TARS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ANIP vs. TARS - Drawdown Comparison

The maximum ANIP drawdown since its inception was -98.81%, which is greater than TARS's maximum drawdown of -77.67%. Use the drawdown chart below to compare losses from any high point for ANIP and TARS.


Loading graphics...

Drawdown Indicators


ANIPTARSDifference

Max Drawdown

Largest peak-to-trough decline

-98.81%

-77.67%

-21.14%

Max Drawdown (1Y)

Largest decline over 1 year

-28.66%

-26.34%

-2.32%

Max Drawdown (5Y)

Largest decline over 5 years

-59.38%

-71.29%

+11.91%

Max Drawdown (10Y)

Largest decline over 10 years

-72.96%

Current Drawdown

Current decline from peak

-82.91%

-14.98%

-67.93%

Average Drawdown

Average peak-to-trough decline

-79.38%

-41.22%

-38.16%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.22%

13.30%

+0.92%

Volatility

ANIP vs. TARS - Volatility Comparison

The current volatility for ANI Pharmaceuticals, Inc. (ANIP) is 9.44%, while Tarsus Pharmaceuticals, Inc. (TARS) has a volatility of 11.44%. This indicates that ANIP experiences smaller price fluctuations and is considered to be less risky than TARS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ANIPTARSDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.44%

11.44%

-2.00%

Volatility (6M)

Calculated over the trailing 6-month period

22.59%

30.30%

-7.71%

Volatility (1Y)

Calculated over the trailing 1-year period

36.90%

45.38%

-8.48%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

47.10%

59.97%

-12.87%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

48.62%

64.52%

-15.90%

Financials

ANIP vs. TARS - Financials Comparison

This section allows you to compare key financial metrics between ANI Pharmaceuticals, Inc. and Tarsus Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
247.06M
151.67M
(ANIP) Total Revenue
(TARS) Total Revenue
Values in USD except per share items